Related Experiment Video
Updated: Feb 19, 2026
08:47
Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates
Published on: March 6, 2019
10.2K
Molecularly defined antibody conjugation through a selenocysteine interface
Thomas Hofer1, Lauren R Skeffington, Colby M Chapman
1Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1203, USA.
Biochemistry
|November 10, 2009
Summary
Researchers developed a novel site-specific antibody conjugation method using selenocysteine. This technique creates highly defined antibody conjugates with precise stoichiometry, improving applications in diagnostics and therapeutics.
Area of Science:
- Bioconjugation Chemistry
- Protein Engineering
- Molecular Biology
Background:
- Conventional antibody conjugation methods produce heterogeneous products with variable stoichiometry.
- There is a high demand for site-specific antibody conjugation to ensure precision and predictability.
- Current methods often lead to batch-to-batch variability, limiting applications.
Purpose of the Study:
- To develop a novel method for site-specific antibody conjugation.
- To utilize the 21st amino acid, selenocysteine, for precise antibody modification.
- To generate molecularly defined antibody conjugates for diverse applications.
Main Methods:
- Employed a mammalian cell expression system to incorporate selenocysteine into IgG and Fab molecules.
- Utilized the unique nucleophilic reactivity of selenocysteine for conjugation.
- Conjugated antibodies with electrophilic derivatives of biotin, fluorescein, and poly(ethylene glycol).
Main Results:
- Generated site-specific antibody conjugates with retained antigen binding capability.
- Demonstrated that IgG conjugates maintained effector functions.
- Showcased gain of function in vitro and in vivo.
- Achieved unique 1:1 stoichiometries of biological and chemical components.
Conclusions:
- Selenocysteine interface technology provides a method for generating highly defined antibody conjugates.
- This approach offers advantages over other site-specific conjugation methods, including no interference with disulfide bridges and no requirement for activation.
- The technology has broad utility in proteomic, diagnostic, and therapeutic applications, including antibody-drug conjugates and radioimmunoconjugates.
